It may simply be an isolated case. However, there is an understandable interest in ensuring that the distinction between genuinely impactful listings and administratively modest changes is maintained, particularly given the care the Albanese Government has previously taken to avoid overstating PBS activity.
An announcement that cost more than the listing, because it would have actually cost something
February 1, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Canberra discovers what it really feels like to face a single buyer, and the response is hypocrisy
November 17, 2026 - - Latest News -
US biotech lobby's call for a White House strategy echoes AusBiotech push
November 17, 2026 - - Latest News -
Third global honour of 2026 for cochlear implant pioneer Graeme Clark
November 17, 2026 - -
Ipsen marks 25 years in Australia as rare disease listings broaden patient access
November 17, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 -

